RUI-products
Official Sponsor
IPT 141 or Bremelanotide, is an isomer of the popular Peptide MT2. It was noted in researching MT2 that many male research subjects experienced the side effects of multiple spontaneous erections and enhanced libido. Further study and research was able to isolate the portion of the MT2 peptide chain responsible for causing this effect. Once isolated it became known as IPT-141.
Further research on IPT-141 yielded some interesting results. While the effects were obvious and undeniable, the mechanism of action for these effects was largely unknown. Further research indicated it activated the melanocortin receptors MC1r and MC4R within the central nervous system, most notably within the hypothalamus in the brain. This made IPT-141 very different from any other compound researched with regards to treating various forms of sexual dysfunction. Unlike PDE5 inhibitors which have a clear cut physiological effect (Inhibiting PDE5 thus increasing NO2 causing vasodilation), IPT-141 exerts its effects via the central nervous system. The initial thought was that IPT-141's effects were strictly neurological, however its impact on the above mentioned melanocortin receptors revealed that it has a specific physiological effect of limiting ischemia, which is blood flow restriction to the extremities.
Research subjects were initially administered IPT-141 via a nasal spray however this route of administration resulted in an inexplicable increase in blood pressure. Further research exploring different routes of administration uncovered that if IPT-141 was administered via subcutaneous injection, the undesirable side effect of hypertension was not observed. The elimination of this adverse side effect rekindled research in this peptide. This second generation of study of IPT-141 revealed some very interesting things.
IPT-141 Exhibits the same potent libido enhancing effects in both males and females. In addition to being effective in both male and female subjects, it was also proven effective in an extremely high percentage of those administered IPT-141. Even cases of extreme sexual dysfunction were able to be restored to normal to above normal sexual function by administration of IPT-141. Also of note, due to different mechanisms of action, IPT-141 was able to be safely and successfully administered alongside a PDE5 inhibitor such as tadafil (cilais), or sildenafil (Viagra) with compounded profound sexual enhancing effects. It was observed that nearly all research subjects administered IPT-141 demonstrated a significant increase in sexual desire and genital arousal.
In a study circa 2006 which ranked positive effects from low to high (high being most positive) The researchers observed a ranking of high for quality of erection, duration of erection, initiation of erection, onset time of arousal, and cardiovascular safety. Across the board IPT-141 showed superior efficacy to any libido enhancing sexual dysfunction treatment including PDE5 inhibitors! This shows profound promise for research in subjects unable to take PDE5 inhibitor due to medicinal or physical adverse interactions.
When combined with PDE5 inhibitors the libido enhancing and sexual performance effect in subjects capable of being administered both was astounding. Researchers observed the highest levels of improvement in every area from sexual desire to sexual arousal and sexual performance. One researcher commented that IPT-141 in addition to it limiting effects on blood flow restriction, changes how research subjects respond to the entire possibility of sexual stimulus.
Overall IPT-1411 offer a very safe, very effective well tolerated, potent libido enhancing as well as sexual performance enhancing peptide. When combined with a PDE5 inhibitor these already potent effects are compounded and the results are nothing short of astounding. It safety and efficacy in both males and females, responders and non-responders to PDE5 inhibitors make this potent peptide one that should be a part of any researcher’s arsenal in the area of sexual performance and enhancement.
For optimal effects this peptide can be combined with any one of our PDE5 Inhibitors found HERE. Good Luck with your research!
Check it out >> iPT-141 10mg - Peptides
Refs:
• King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H (2007). "Melanocortin receptors, melanotropic peptides and penile erection". Current Topics in Medicinal Chemistry 7 (11): 1098–1106. PMC 2694735. PMID 17584130.
• ^ Bremelanotide for Organ Protection and Related Indications, Palatin Technologies fact sheet. Retrieved on 2009-01-18.
• ^ "Palatin Technologies Completes Enrollment in Phase 2B Bremelanotide Female Sexual Dysfunction Trial". The Bradenton Herald. Retrieved 2012-03-08.
*Ann N Y Acad Sci. 2003 Jun;994:96-102.PT-141: a melanocortin agonist for the treatment of sexual dysfunction.Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY.SourcePalatin Technologies, Inc, Cranbury, New Jersey 08512, USA.
*Int J Impot Res. 2004 Apr;16(2):135-42.Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB.SourceDepartment of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08554-5653, USA. rosen@umdnj.edu
*Curr Opin Investig Drugs. 2004 Apr;5(4):456-62.PT-141 Palatin.Hedlund P.SourceDepartment of Clinical Pharmacology, University of Lund, F-blocket, Universitetssjukhuset, 22185 Lund, Sweden. petter.hedlund@klinfarm.lu.se
Further research on IPT-141 yielded some interesting results. While the effects were obvious and undeniable, the mechanism of action for these effects was largely unknown. Further research indicated it activated the melanocortin receptors MC1r and MC4R within the central nervous system, most notably within the hypothalamus in the brain. This made IPT-141 very different from any other compound researched with regards to treating various forms of sexual dysfunction. Unlike PDE5 inhibitors which have a clear cut physiological effect (Inhibiting PDE5 thus increasing NO2 causing vasodilation), IPT-141 exerts its effects via the central nervous system. The initial thought was that IPT-141's effects were strictly neurological, however its impact on the above mentioned melanocortin receptors revealed that it has a specific physiological effect of limiting ischemia, which is blood flow restriction to the extremities.
Research subjects were initially administered IPT-141 via a nasal spray however this route of administration resulted in an inexplicable increase in blood pressure. Further research exploring different routes of administration uncovered that if IPT-141 was administered via subcutaneous injection, the undesirable side effect of hypertension was not observed. The elimination of this adverse side effect rekindled research in this peptide. This second generation of study of IPT-141 revealed some very interesting things.
IPT-141 Exhibits the same potent libido enhancing effects in both males and females. In addition to being effective in both male and female subjects, it was also proven effective in an extremely high percentage of those administered IPT-141. Even cases of extreme sexual dysfunction were able to be restored to normal to above normal sexual function by administration of IPT-141. Also of note, due to different mechanisms of action, IPT-141 was able to be safely and successfully administered alongside a PDE5 inhibitor such as tadafil (cilais), or sildenafil (Viagra) with compounded profound sexual enhancing effects. It was observed that nearly all research subjects administered IPT-141 demonstrated a significant increase in sexual desire and genital arousal.
In a study circa 2006 which ranked positive effects from low to high (high being most positive) The researchers observed a ranking of high for quality of erection, duration of erection, initiation of erection, onset time of arousal, and cardiovascular safety. Across the board IPT-141 showed superior efficacy to any libido enhancing sexual dysfunction treatment including PDE5 inhibitors! This shows profound promise for research in subjects unable to take PDE5 inhibitor due to medicinal or physical adverse interactions.
When combined with PDE5 inhibitors the libido enhancing and sexual performance effect in subjects capable of being administered both was astounding. Researchers observed the highest levels of improvement in every area from sexual desire to sexual arousal and sexual performance. One researcher commented that IPT-141 in addition to it limiting effects on blood flow restriction, changes how research subjects respond to the entire possibility of sexual stimulus.
Overall IPT-1411 offer a very safe, very effective well tolerated, potent libido enhancing as well as sexual performance enhancing peptide. When combined with a PDE5 inhibitor these already potent effects are compounded and the results are nothing short of astounding. It safety and efficacy in both males and females, responders and non-responders to PDE5 inhibitors make this potent peptide one that should be a part of any researcher’s arsenal in the area of sexual performance and enhancement.
For optimal effects this peptide can be combined with any one of our PDE5 Inhibitors found HERE. Good Luck with your research!
Check it out >> iPT-141 10mg - Peptides
Refs:
• King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H (2007). "Melanocortin receptors, melanotropic peptides and penile erection". Current Topics in Medicinal Chemistry 7 (11): 1098–1106. PMC 2694735. PMID 17584130.
• ^ Bremelanotide for Organ Protection and Related Indications, Palatin Technologies fact sheet. Retrieved on 2009-01-18.
• ^ "Palatin Technologies Completes Enrollment in Phase 2B Bremelanotide Female Sexual Dysfunction Trial". The Bradenton Herald. Retrieved 2012-03-08.
*Ann N Y Acad Sci. 2003 Jun;994:96-102.PT-141: a melanocortin agonist for the treatment of sexual dysfunction.Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY.SourcePalatin Technologies, Inc, Cranbury, New Jersey 08512, USA.
*Int J Impot Res. 2004 Apr;16(2):135-42.Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB.SourceDepartment of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08554-5653, USA. rosen@umdnj.edu
*Curr Opin Investig Drugs. 2004 Apr;5(4):456-62.PT-141 Palatin.Hedlund P.SourceDepartment of Clinical Pharmacology, University of Lund, F-blocket, Universitetssjukhuset, 22185 Lund, Sweden. petter.hedlund@klinfarm.lu.se
